Before starting treatment
Molecular diagnosisThe presence of the FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) must be confirmed, prior to a patient with AML receiving midostaurin, using a validated test. 1 The...
Twitter Linkedin Facebook Pinterest Google plusDuring treatment
Check the number of white blood cells regularly 1 For signs and symptoms of infection, including infections related to infusions and catheters. If an infection has been diagnosed, appropriate treatment should be instituted immediately,...Twitter Linkedin Facebook Pinterest Google plusSafety Profile
Please refer to the complete product information for a comprehensive description of side effects. It is essential to be mindful of these side effects. Carefully check for signs and symptoms of possible side effects and report any side effects to LAREB...
Twitter Linkedin Facebook Pinterest Google plusSpecial patient groups
On this page you will find information on the use of midostaurin in special patient groups, for example:
Elderly (≥ 65 years) The patients with renal impairment The patients with hepatic impairment The patients with acute promyelocytic leukaemia...Twitter Linkedin Facebook Pinterest Google plusDosage recommendations
Treatment with midostaurin should be initiated by a physician experienced in the use of medicine for cancer. 1
Twitter Linkedin Facebook Pinterest Google plusGuidelines
HOVON treatment advice with regard to AML patients with FLT3-ITD or FLT3-TKD gene mutations 1.2 In its most recent treatment guideline (October 2018), HOVON recommends the following: AML patients with...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
The efficacy and safety of midostaurin in AML patients has been studied in the RATIFY study.
The RATIFY study is a randomised, double-blind, placebo-controlled international study conducted in 717 patients (18-59 years) with newly diagnosed...
Twitter Linkedin Facebook Pinterest Google plusRATIFY: Primary endpoint: Overall survival
The RATIFY study demonstrated significant and sustained survival benefits in adult patients with newly diagnosed acute myeloid leukaemia (AML) with FLT3 mutation receiving midostaurin. 1 The overall survival of patients in the midostaurin...Twitter Linkedin Facebook Pinterest Google plusRATIFY: Secondary endpoints
Event-free survival (EFS) The key secondary endpoint in the RATIFY study was the event-free survival. 1 The patients receiving midostaurin plus standard chemotherapy had a longer EFS compared to patients receiving standard...Twitter Linkedin Facebook Pinterest Google plus